Top

Published in:

01-12-2016

Long-term health effects among testicular cancer survivors

Published in: Journal of Cancer Survivorship | Issue 6/2016

Abstract

Purpose

Testicular cancer is diagnosed at a young age and survival rates are high; thus, the long-term effects of cancer treatment need to be assessed. Our objectives are to estimate the incidence rates and determinants of late effects in testicular cancer survivors.

Methods

We conducted a population-based cohort study of testicular cancer survivors, diagnosed 1991–2007, followed up for a median of 10 years. We identified 785 testicular cancer patients who survived ≥5 years and 3323 men free of cancer for the comparison group. Multivariate Cox regression analysis was used to compare the hazard ratio between the cases and the comparison group and for internal analysis among case patients.

Results

Testicular cancer survivors experienced a 24 % increase in risk of long-term health effects >5 years after diagnosis. The overall incidence rate of late effects among testicular cancer survivors was 66.3 per 1000 person years. Higher risks were observed among testicular cancer survivors for hypercholesterolemia, infertility, and orchitis. Chemotherapy and retroperitoneal lymph node dissection appeared to increase the risk of late effects. Being obese prior to cancer diagnosis appeared to be the strongest factor associated with late effects.

Conclusions

Testicular cancer survivors were more likely to develop chronic health conditions when compared to cancer-free men.

Implications for Cancer Survivors

While the late effects risk was increased among testicular cancer survivors, the incidence rates of late effects after cancer diagnosis was fairly low.

American Cancer Society. Cancer treatment and survivorship facts and figures, 2014–2015. Atlanta: American Cancer Society; 2014.

Ferlay J SHR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10, http://globocan.iarc.fr.

Fast Stats: an interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. http://seer.cancer.gov/faststats. 2013.

Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International patterns and trends in testis cancer incidence. Int J Cancer. 2005;115(5):822–7.CrossRefPubMed

Ries LAG YJL, Keel GE, Eisner MP, Lin YD, Horner M-J. SEER Survival monograph: cancer survival among adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD 2007.

Haugnes HS, Bosl GJ, Boer H et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012; 30(1527-7755 (Electronic))(0732-183X (Linking))(30), 3752–3763.

Covielle VBM. Cumulative incidence estimation in the presence of competing risks. STATA. 2004;4(2):103–12.

Crowther M.J. LPC. stgenreg: A Stata package for general parametric survival analysis. J Stat. Soft. 2013; 53(12):1–17.

Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, de Vries EG, Sleijfer DT. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev. 2000;26(6):429–47.CrossRefPubMed

10.

van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006;24(3):467–75.CrossRefPubMed

11.

Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513–23.CrossRefPubMed

12.

Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649–57.CrossRefPubMed

13.

Centers for Disease Control and Prevention (CDC). Behavioral risk factor surveillance system survey data. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2014.

14.

NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer 1.2013. National Comprehensive Cancer Network, 2013.

15.

Beard CJ, Travis LB, Chen MH, et al. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer. 2013;119(15):2771–7.CrossRefPubMedPubMedCentral

16.

Willemse PM, Burggraaf J, Hamdy NA, et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer. 2013;109(1):60–7.CrossRefPubMedPubMedCentral

17.

Gietema JA, Sleijfer DT, Willemse PH et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med. 1992; 116(0003-4819 (Print))(0003-4819 (Linking))(9), 709–715.

18.

Meinardi MT, Gietema JA, van dG,WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000; 18(0732-183X (Print))(0732-183X (Linking))(8), 1725–1732.

19.

Haugnes HS, Aass N, Fossa SD, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol. 2007;18(2):241–8.CrossRefPubMed

20.

Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008; 299(1538-3598 (Electronic))(0098-7484 (Linking))(6), 672–684.

21.

Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. 2010;116(10):2322–31.PubMed

22.

Rossen PB, Pedersen AF, Zachariae R, von der Maase H. Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol. 2009;27(35):5993–9.CrossRefPubMed

23.

Oldenburg J, Fossa SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 2006;15(5):791–800.CrossRefPubMed

24.

Brydoy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101(24):1682–95.CrossRefPubMedPubMedCentral

25.

http://www.census.gov/hhes/migration/data/acs/state-to-state.html.

Title: Long-term health effects among testicular cancer survivors
Publication date: 01-12-2016
Published in: Journal of Cancer Survivorship / Issue 6/2016
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-016-0548-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 6/2016

Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors

Erratum to: Prevalence and factors related to smoking and smoking cessation 6 months following a cancer diagnosis: a population-based study

Trends in cancer survivors’ experience of patient-centered communication: results from the Health Information National Trends Survey (HINTS)

The “Big C”—stigma, cancer, and workplace discrimination

The role of the GP in follow-up cancer care: a systematic literature review

Health insurance coverage, care accessibility and affordability for adult survivors of childhood cancer: a cross-sectional study of a nationally representative database

Keynote webinar | Spotlight on antibody–drug conjugates in cancer